Literature DB >> 33767924

Retinal Tamponades: Current Uses and Future Technologies.

Avnish Deobhakta1, Richard Rosen1.   

Abstract

PURPOSE OF REVIEW: In this article, the current use and limitations of existing retinal tamponades are discussed. Potential novel developments that address those limitations are subsequently highlighted, along with areas of future improvements. RECENT
FINDINGS: While retinal tamponades have existed for decades and improved the treatment of retinal detachments, many problems still exist with their use, including inadequate tamponade of the inferior retina, toxicity from retained heavy liquids, glaucoma, and keratopathy, among others. New advancements in the components of heavy liquids and vitreous substitutes aim to mitigate those issues.
SUMMARY: Existing retinal tamponades, including perflurocarbon heavy liquids, fluorinated gases, and silicone oil, have specific limitations that cause potentially avoidable morbidity. New developments, such as heavy silicone oil, novel vitreous gels, and future avenues of approach, such as potentially reabsorbing heavy liquids may help increase our ability to treat retinal detachments with fewer complications.

Entities:  

Keywords:  Heavy Fluid; Perfluorocarbon Liquid; Retinal Detachment; Silicone Oil; Tamponade; Vitreous

Year:  2020        PMID: 33767924      PMCID: PMC7987123          DOI: 10.1007/s40135-020-00247-9

Source DB:  PubMed          Journal:  Curr Ophthalmol Rep        ISSN: 2167-4868


  59 in total

1.  Anterior chamber gas bubble following pneumatic retinopexy in a young, phakic patient.

Authors:  Colin Sh Tan; Kent Wee; Min-Dinn Zaw; Tock H Lim
Journal:  Clin Exp Ophthalmol       Date:  2011-04       Impact factor: 4.207

Review 2.  The epidemiology of rhegmatogenous retinal detachment: geographical variation and clinical associations.

Authors:  D Mitry; D G Charteris; B W Fleck; H Campbell; J Singh
Journal:  Br J Ophthalmol       Date:  2009-06-09       Impact factor: 4.638

3.  SURGICAL OUTCOMES OF 25-GAUGE PARS PLANA VITRECTOMY USING AIR AS AN INTERNAL TAMPONADE FOR PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT.

Authors:  Yunyun Li; Ning Cheung; Liyun Jia; Hui Zhang; Ningpu Liu
Journal:  Retina       Date:  2020-11       Impact factor: 4.256

4.  Mechanisms of intraocular pressure elevation after pars plana vitrectomy.

Authors:  D P Han; H Lewis; F H Lambrou; W F Mieler; A Hartz
Journal:  Ophthalmology       Date:  1989-09       Impact factor: 12.079

5.  Tensile strength of chorioretinal lesions produced by photocoagulation, diathermy, and cryopexy.

Authors:  H Zauberman
Journal:  Br J Ophthalmol       Date:  1969-11       Impact factor: 4.638

Review 6.  Proliferative vitreoretinopathy: risk factors and pathobiology.

Authors:  J Carlos Pastor; E Rodríguez de la Rúa; Francisco Martín
Journal:  Prog Retin Eye Res       Date:  2002-01       Impact factor: 21.198

7.  Patching retinal breaks with Seprafilm for treating retinal detachments in humans: 9 years of follow-up.

Authors:  M Haruta; M Arai; J Sueda; T Hirose; R Yamakawa
Journal:  Eye (Lond)       Date:  2017-01-27       Impact factor: 3.775

8.  Low viscosity liquid fluorochemicals in vitreous surgery.

Authors:  S Chang
Journal:  Am J Ophthalmol       Date:  1987-01-15       Impact factor: 5.258

9.  Silicone oil in the repair of complex retinal detachments. A prospective observational multicenter study.

Authors:  S P Azen; I U Scott; H W Flynn; M Y Lai; T M Topping; L Benati; D K Trask; L A Rogus
Journal:  Ophthalmology       Date:  1998-09       Impact factor: 12.079

Review 10.  Complications Associated with the Use of Expandable Gases in Vitrectomy.

Authors:  Piotr Kanclerz; Andrzej Grzybowski
Journal:  J Ophthalmol       Date:  2018-11-18       Impact factor: 1.909

View more
  1 in total

1.  New technique for removal of perfluorocarbon liquid related sticky silicone oil and literature review.

Authors:  Hai-Shuang Lin; Yong-Ping Tang; Lu Zhang; En-Ze Liu; Ling-Ying Ye; Ming-Na Xu; Rong-Han Wu; Zhi-Xiang Hu
Journal:  Int J Ophthalmol       Date:  2021-12-18       Impact factor: 1.779

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.